MIMETAS joins new alliance to advance microphysiological systems in drug development
MIMETAS, the Dutch organ-on-a-chip specialist, is among nine founding members of IAMPS – the Industry Alliance for Microphysiological Systems – launched on 10 February 2026 as the world’s first industry association dedicated to microphysiological systems (MPS) technologies.
The alliance brings together AlveoliX (Switzerland), BiomimX (Italy), chiron (Netherlands), Dynamic42 (Germany), InSphero (Switzerland), MIMETAS (Netherlands), NETRI (France), React4Life (Italy), and TissUse (Germany). Collectively, these companies develop organoids, organs-on-chips, and next-generation human biology platforms designed to provide more predictive and ethically sound alternatives to traditional animal and two-dimensional cell culture models.
Regulatory and scientific objectives
IAMPS has outlined a clear agenda: accelerating regulatory acceptance of MPS technologies, progressing qualification and standardisation, strengthening European biobanking and tissue access, and contributing to strategic EU investment. For clinical laboratory scientists, the standardisation agenda is particularly significant, as harmonised frameworks will be essential to integrating MPS-derived data into drug development workflows and, ultimately, regulatory submissions.
Leadership and industry perspective
The alliance is led by Thibault Honegger of NETRI as President, with Paola Occhetta of BiomimX serving as Vice-President for Regulatory Adoption. Jos Joore, CEO of MIMETAS, takes the role of Vice-President for Legislation and Programmes. Joore commented: “Microphysiological systems are becoming essential to the future of drug development: human-relevant, scalable, and transforming how therapies are discovered and evaluated. By uniting leading innovators across the field, we can drive harmonised standards and deliver the scientific rigour needed to make MPS the worldwide norm for safe, fast, and effective drug development.”
MIMETAS operates globally through its OrganoPlate® platform, offering threedimensional human tissue models for pharmaceutical drug discovery across sites in the United States, Europe, and Asia.
